AI assistant
Sending…
CRESCENT BIOPHARMA, INC. — Director's Dealing 2017
Sep 19, 2017
33678_dirs_2017-09-18_3cba011d-a512-49a2-8214-c6d7dbd79bc4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2017-09-18
Reporting Person: Thackray Helen M. (SVP Clinical Development, CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-09-18 | Common Stock | S | 2000 | $13.00 | Disposed | 150615 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on June 19, 2017.
More from CRESCENT BIOPHARMA, INC.
Regulatory Filings
2026
Jun 3
Earnings Release
2026
Feb 26
Annual Report
2026
Feb 26
Major Shareholding Notification
2026
Feb 5
Capital/Financing Update
2026
Jan 15
Capital/Financing Update
2026
Jan 7
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17